ABOUT US

CALL TO ORDER

301-471-1269

240-440-2662

EMAIL TO ORDER

info@fibercellsystems.com

Technical Documents

HomeFiberCell Systems   /  Technical Resources   /  Technical Documents

Technical Documents

Presentations and Posters

  1. Poster: FiberCell Systems ISEV 2022 – Retroviral Transduction and Production of Palm-GRET Labelled Extracellular Vesicles using Bone Marrow Derived MSC in a Hollow Fiber Bioreactor
  2. Poster: FiberCell Systems ISEV 2022 – Scalability of Production and Bio-Activity of Amniotic Fluid Stem Cell Extracellular Vesicles from 3-D Hollow Fiber Bioreactor and 2-D Culture
  3. Poster: FiberCell Systems ISEV 2020 – Amniotic stem cell EVs produced in a 3-D hollow fiber bioreactor have enhanced bioactivity when compared to 2-D petri dish EVs, with yields that can support clinical applications in a cGMP-compatible system
  4. Webinar: Beyond 3-D: Recapitulating Nature for Optimal Bioproduction – Also see PPT file
  5. Presentation: FiberCell Systems Technical Presentation 2017
  6. Presentation: FiberCell Systems – Hollow Fiber Bioreactors
  7. Presentation: FiberCell Systems – Hollow Fiber Infection Model for Antibiotic PK/PD
  8. Presentation: FiberCell Systems – Production of Exosomes and Culture of Stem Cells in Hollow Fiber Bioreactors
  9. Poster: FiberCell Systems – Continuous Collection of Stem Cells from a Human Placenta Perfusion Co-Culture
  10. Poster: ZenBio – Scalable production of exosomes and their potential use as a therapeutic for tendinopathy
  11. Poster: FiberCell Systems ISEV 2016 – Large Scale Production of Extracellular Vesicles in a Hollow Fiber Bioreactor System
  12. Poster: FiberCell Systems ISEV 2017 – Clinical Scale Production and Wound Healing Activity of Human Adipose-Derived Mesenchymal Stem Cell Extracellular Vesicles from a Hollow Fiber Bioreactor
  13. Presentation: “3-D Hollow Fiber Bioreactors, a Better Way to Grow Cells”  presentation from the 2023 CellMe Berlin-International Forum on Cell Manufacturing and Engineering

Publications

  1. Oligodendroglia-derived extracellular vesicles activate autophagy via LC3B/BAG3 to protect against oxidative stress with an enhanced efect for HSPB8 enriched vesicles
  2. Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model
  3. Electrodeposited Magnetic Nanoporous Membrane (MNM) with a Multi-Edge Superparamagnetic Heterogeneous Wedge Junction for High-Yield and High-Throughput Immunocapture of Specimen
  4. Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow- Fiber Model of Mycobacterium kansasii Infection
  5. Mesenchymal Stromal Cell Bioreactor for Ex Vivo Reprogramming of Human Immune Cells
  6. Hollow Fiber Bioreactor Protocol for Mesenchymal Stem Cells
  7. Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model
  8. Hollow fiber bioreactor production of extracellular vesicles from human bone marrow mesenchymal stromal cells yields nanovesicles that mirrors the immunomodulatory antigenic signature of the producer cell
  9. Rational Design for Controlled Release of Dicer-substrate SiRNA Harbored in phi29 pRNA-based Nanoparticles
  10. Standard therapy of MAC pulmonary disease shows limited efficacy in HFIM
  11. Application of the Hollow Fibre Infection Model (HFIM) in Antimicrobial Development: A Systematic Review and Recommendations of Reporting
  12. Polymyxin B Pharmacodynamics in the Hollow Fiber Infection Model: What You See May Not Be What You Get
  13. Leveraging the Dynamic in Vitro Hollow Fiber Infection Model in Determining Optimal Clinical Dose of β-Lactam and β-Lactamase Inhibitor Combinations
  14. Hollow-fiber bioreactor production of extracellular vesicles from human bone marrow mesenchymal stromal cells yields nanovesicles that mirrors the immunomodulatory antigenic signature of the producer cell
  15. FiberCell Systems Bioreactor Harvesting EVs from Cells in Continuous High-Density Culture
  16. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model
  17. Osteosarcoma-Derived Extracellular Vesicles Induce Lung Fibroblast Reprogramming
  18. Pharmacodynamic evaluation of plasma and epithelial lining fluid exposures of amikacin against Pseudomonas aeruginosa in a dynamic in vitro hollow-fibre infection model
  19. Immunization with Human Cytomegalovirus Core Fusion Machinery and Accessory Envelope Proteins Elicit Strong Synergistic Neutralizing Activities
  20. Reference List Sorted by Drug Organism and Cartridge
  21. Pump Settings for in-vitro Hollow-fiber Experiments
  22. Hollow Fiber System of Tuberculosis Laboratory Manual
  23. Mimicking in-vivo Exposures to Drug Combinations In-vitro: Anti-tuberculosis Drugs in Lung Lesions and the Hollow Fiber Model of Infection
  24. Hypoxia-induced Tumor Exosomes Promote M2-like Macrophage Polarization of Infiltrating Myeloid Cells and MicroRNA-mediated Metabolic Shift
  25. Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus
  26. Babesia bigemina: Advances in continuous in vitro culture using serum-free medium supplemented with insulin, transferrin, selenite, and putrescine
  27. Stem Cell Health and Tissue Regeneration in Microgravity
  28. Space Tissue Loss – Stem Cell Regeneration (STL-Regeneration)
  29. A Hollow-Fiber Infection Model to Evaluate the Prevention of On-Therapy Resistance of Neisseria gonorrhoeae to Gepotidacin
  30. Critical Path to Tuberculosis Drug Regimens: Global Collaboration to Accelerate Development of Novel Drug Regimens and Rapid Drug Susceptibility Tests for Tuberculosis
  31. Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model
  32. An update on technical, interpretative and clinical relevance of antimicrobial synergy testing methodologies
  33. Novel Therapy Targeting the Cryptosporidium Virus
  34. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system
  35. Efficient production and enhanced tumor delivery of engineered extracellular vesicles
  36. Secretomic profiling of cells from hollow fiber bioreactor reveals PSMA3 as a potential cholangiocarcinoma biomarker
  37. Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era
  38. Collection of in vivo-like liver cell secretome with alternative sample enrichment method using a hollow fiber bioreactor culture system combined with tangential flow filtration for secretomics analys
  39. Secretome analysis using a hollow fiber culture system for cancer biomarker discovery
  40. U.S. Secretary of Commerce Penny Pritzker Announces Biopharmaceutical Manufacturing Institute Joining Manufacturing USA Network
  41. Culture of Placental Derived Cells in a Hollow Fiber Bioreactor Cartridge
  42. A Development Paradigm for Novel Combination Regimens for Multidrug-Resistant and Drug-Susceptible Tuberculosis in Children
  43. Researchers Develop First-ever Tuberculosis Treatment for Children
  44. ISEV 2015 Exosome Production
  45. The Hollow Fiber Infection Model: Principles and Practice
  46. Continuous Production of Exosomes Utilizing the Technical Advantages of Hollow-Fiber Bioreactor Technology
  47. Simulated Antibiotic Exposures in an In Vitro Hollow-Fiber Infection Model
  48. Co-Culture of Stromal and Erythroleukemia Cells in a Perfused Hollow Fiber Bioreactor System
  49. Single-Use, Continuous Processing of Primary Stem Cells
  50. The Hollow Fiber Infection Model for Antimicrobial Pharmacodynamics and Pharmacokinetics
  51. Antiviral Pharmacodynamics in Hollow Fiber Bioreactors
  52. Isoniazid’s Bactericidal Activity Ceases
  53. Optimizing the culture of Plasmodium falciparum in hollow fiber bioreactors
  54. Insights into Egg Coat Assembly and Egg-Sperm Interaction from the X-Ray Structure of Full-Length ZP
  55. In vitro Toxicology and Hollow Fiber Bioreactors
  56. Considerations in Scale-Up of Viral Vaccine Production
  57. The Hollow Fiber Bioreactor and Cell Co-Cultivation